Benzinga | Apr 16, 2021 06:11AM EDT

Goldman Sachs Initiates Coverage On Editas Medicine with Sell Rating, Announces Price Target of $20

Goldman Sachs analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Sell rating and announces Price Target of $20.